• Striving to Bring Back The Magic of Normal

    Patient-first. Science-based. Employee-driven.

Pharmacyclics is an AbbVie company based in Silicon Valley, California and focused on developing and commercializing small-molecule medicines for the treatment of cancers and immune-mediated diseases for which there is great unmet medical need. We seek to discover innovative therapies to improve standards of care and strive to help our patients rediscover the Magic of Normal.

Company Statement: Important Update for Healthcare Professionals and Patients Regarding IMBRUVICA® (ibrutinib)

A Message From Our President

Watch a video with Erik von Borcke, President, Pharmacyclics, an AbbVie Company, discussing who we are and why we strive to bring back the Magic of Normal for patients. 

Our Culture

At Pharmacyclics, our patients motivate and inspire us to push the boundaries of science. We strive to make a difference in their lives. It’s not only our mission, but our passion.

IMBRUVICA® (ibrutinib)

For more information on IMBRUVICA® (ibrutinib) a Bruton's tyrosine kinase (BTK) inhibitor, please visit:
www.imbruvica.com

Join the Team

Visit our Careers page to learn about our Mode of Action and the exciting opportunities available at Pharmacyclics, an AbbVie company.